UNSPSC 51386603: Aloe/hydrocortisone/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386603 Aloe/hydrocortisone/pramoxine is a Commodity code that in practice captures pharmaceutical and medical supply procurement by state and local health agencies, though recent activity shows the code is being applied to acquisitions that diverge significantly from its nominal scope. The single recent opportunity in the record — Seminole County, Florida's solicitation for naloxone and drug deactivation systems — sits outside the topical bounds of the code's stated product line (a localized dermatological preparation). State and local governments soliciting under this code appear to include county health departments and community health agencies, though the sparse activity record limits visibility into the full issuing-body mix or any repeat buyers at the Commodity level.

The geographic spread of recent opportunities under this code is represented by Florida, specifically Seminole County. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The IFB response deadline was July 26, 2023 (a historical date inconsistent with the June 2026 posting). The contract carries a two-year initial term with an optional one-year renewal, unit-price bidding, and E-Verify compliance requirements. FEMA funding is potentially involved, introducing federal regulatory overlays. Beyond this single opportunity, the code shows minimal recent state and local activity.